Pre-made Ensomafusp Alfa benchmark antibody (Bispecific, anti-CD19;TNFRSF9 therapeutic antibody, Anti-B4/CVID3;ILA/4-1BB/CDw137 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Pre-made Ensomafusp Alfa benchmark antibody (Bispecific, anti-CD19;TNFRSF9 therapeutic antibody, Anti-B4/CVID3;ILA/4-1BB/CDw137 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-INN-836
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Products Name (INN Index) | Pre-Made Ensomafusp Alfa Alfaiosimilar, Bispecific, Anti-Cd19; Tnfrsf9 Antibody: Anti-B4/CVID3;ILA/4-1BB/CDw137 therapeutic antibody |
---|---|
INN Name | ensomafusp alfa |
Target | CD19 |
Format | Bispecific |
Derivation | NA |
Species Reactivity | NA |
CH1 Isotype | NA |
VD LC | NA |
Highest_Clin_Trial (Jan '20) | NA |
Est. Status | NA |
100% SI Structure | NA |
99% SI Structure | NA |
95-98% SI Structure | NA |
Year Proposed | NA |
Year Recommended | NA |
Companies | NA |
Conditions Approved | NA |
Conditions Active | NA |
Conditions Discontinued | NA |
Development Tech | NA |
Previous Name | NA |
Gm Offical Target Name | CD19,TNFRSF9 |
Package |
Genemeidi Omicron Variant Products
test
Previous slide
Next slide